Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating.
Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S. launch of MNEXT Spike, improved operational efficiency, and disciplined expense controls as key contributors. CEO Stéphane Bancel highlighted that operating expenses fell by 31% year over year, while President Stephen Hoge noted, “MNEXT Spike quickly became our leading product in the U.S.” The leadership acknowledged ongoing challenges, particularly the uncertainty caused by the FDA’s refusal to file letter on the mRNA-1010 flu vaccine, which management described as a source of “real challenges for businesses, patients, and the broader innovation ecosystem.”
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the company's application for its new seasonal flu vaccine.
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a turbulent four-year period of consolidation and the "Great Rationalization," a surge of institutional capital and the industrialization of Artificial Intelligence (AI) have ignited
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based biotechnology pioneer is now fighting to prove that its messenger RNA (mRNA) platform is a "one-hit wonder" no more. The company has dominated recent financial [...]
It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2% above analysts’ consensus estimates.
